Autoimmune diseases

Pediatric Alopecia Areata (LH-8)

LH-8 (Topical Coacillium 21%) is currently in a Phase 2/3 pivotal study, aims to be the first treatment for Pediatric Alopecia Areata (AA). Pediatric AA is a chronic, debilitating autoimmune skin disease that causes hair loss on the scalp, face and sometimes on other areas of the body. Both genders and all ethnic groups can develop alopecia areata and can be different for every child who has it.

Trial data

RAAINBOW review

About our trials About the condition

Oncology Supportive Care

Chemotherapy Induced Alopecia (LH-4)

LH-4 (Topical Coacillium 42%) aims to be the first treatment for Chemotherapy Induced Alopecia (CIA). Alopecia is one of the most common adverse events caused by numerous chemotherapy drugs. While not a life-threatening event, it has a significantly negative psychological and social impact, with repercussions on various aspects of patients quality of life. We have several trials and the program is currently in Ph 2.

• Trials data
• VOLUME publication
• CARA RELAC poster

About the condition

Oncology Supportive Care

Cancer Related Fatigue (LH-10)

LH-10 (Oral Coacillium) has completed one Pre-clinical study in mice, aims to be the first treatment for Cancer Related Fatigue (CRF). It is the most commonly reported symptom in patients and has a deep consequence on the patient's quality of life, including physical, psychosocial, and economic/occupational aspects. CRF arises from the cancer itself or can be a side effect of cancer treatments.

• Trial data
• STRENCE poster

About the condition